Aurobindo plans domestic formulation foray, sets 1000 cr sales target in next 3yrs

Aurobindo Pharma is largely an export oriented drug maker, while it does have an India business which is business-to-business (B2B) involving sale of active pharmaceutical ingredients to other drug makers. Aurobindo has net cash of $211 million as on December 2021. The drug maker is also in the process of restructuring its business which involves demerger of injectable business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a50iESe
via IFTTT

0 comments:

Post a Comment